Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang(National Taiwan University Hospital), Lecia V. Sequist(Harvard University), Ki Hyeong Lee(Chungbuk National University Hospital), Caicun Zhou(Tongji University), С. В. Орлов(St Petersburg University), Wu‐Chou Su(National Cheng Kung University Hospital), Jaafar Bennouna(Hôpital Foch), Nobuyuki Yamamoto(Wakayama Medical University), Kenneth J. O’Byrne(Translational Research Institute), Martin Schüler(German Cancer Research Center), Vera Hirsh(Taipei Veterans General Hospital), Dan Massey(Taipei Veterans General Hospital), Sanjay Popat(Royal Marsden NHS Foundation Trust), Sarayut Lucien Geater(Prince of Songkla University), Tony Mok(Chinese University of Hong Kong), Kye Young Lee(Konkuk University Medical Center), Victoria Zazulina(Taipei Veterans General Hospital), Michael Boyer(Chris O’Brien Lifehouse), Terufumi Kato(Taipei Veterans General Hospital), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jifeng Feng(Zhejiang Cancer Hospital), Yunchao Huang(Kunming Medical University), В. А. Горбунова(Taipei Veterans General Hospital), Mehdi Shahidi(Taipei Veterans General Hospital), Chun-Ming Tsai(Taipei Veterans General Hospital), Martin Sebastian(Goethe University Frankfurt), Cheng-Ping Hu(Central South University), Shun Lü(Shanghai Jiao Tong University)
Cited by 1,578
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k